Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 10,700 shares of the stock in a transaction on Wednesday, January 18th. The shares were purchased at an average cost of $8.87 per share, with a total value of $94,909.00. Following the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $27,221,595.37. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
Phillip Md Et Al Frost also recently made the following trade(s):
Shares of Opko Health Inc. (NASDAQ:OPK) traded down 2.56% on Thursday, hitting $8.75. The stock had a trading volume of 5,594,130 shares. The stock’s market cap is $4.88 billion. Opko Health Inc. has a one year low of $7.42 and a one year high of $12.15. The company’s 50 day moving average is $10.55 and its 200 day moving average is $10.08.
Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Monday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The firm earned $298 million during the quarter, compared to analysts’ expectations of $322 million. Opko Health had a negative net margin of 0.81% and a negative return on equity of 0.49%. The firm’s revenue for the quarter was up 108.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.25 earnings per share. Equities research analysts predict that Opko Health Inc. will post ($0.07) EPS for the current fiscal year.
Several brokerages recently weighed in on OPK. Ladenburg Thalmann restated a “buy” rating and issued a $19.50 price target (down previously from $20.00) on shares of Opko Health in a research note on Tuesday, January 3rd. Jefferies Group restated a “hold” rating and issued a $10.00 price target on shares of Opko Health in a research note on Monday, October 10th. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Opko Health in a research note on Monday, October 10th. Zacks Investment Research upgraded Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, October 25th. Finally, Standpoint Research restated a “buy” rating on shares of Opko Health in a research note on Friday, December 30th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. Opko Health currently has a consensus rating of “Hold” and an average target price of $15.21.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its position in Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock valued at $10,038,000 after buying an additional 28,700 shares in the last quarter. Whalerock Point Partners LLC purchased a new position in Opko Health during the third quarter valued at about $2,100,000. Piedmont Investment Advisors LLC purchased a new position in Opko Health during the third quarter valued at about $622,000. Finally, LPL Financial LLC boosted its position in Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock valued at $142,000 after buying an additional 504 shares in the last quarter. 22.24% of the stock is owned by hedge funds and other institutional investors.
About Opko Health
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.